title: Combination chemotherapy followed by radiation therapy in patients with regional stage III unresectable non-small cell lung cancer.
abstract: A chemotherapy combination of cyclophosphamide, doxorubicin, and cisplatin (CAP) was administered to 30 patients with stage III M0 or M1 (supraclavicular nodes) unresectable non-small cell lung cancer before and after radiotherapy. All patients had mediastinal metastases and most had T2 or T3 primary lesions. The response rate (complete plus partial) after two cycles of CAP was 47%, which increased to 66% (24% complete response rate) following radiotherapy. The overall median survival from initiation of chemotherapy was 9 months. CNS relapse occurred in five (26%) of 19 responding patients who did not receive prophylactic cranial irradiation in the early part of the study.
authors.forename: R
authors.initials: R
authors.lastname: Fram
authors.forename: A
authors.initials: A
authors.lastname: Skarin
authors.forename: J
authors.initials: J
authors.lastname: Balikian
authors.forename: D
authors.initials: D
authors.lastname: Amato
authors.forename: N
authors.initials: N
authors.lastname: Leslie
authors.forename: A
authors.initials: A
authors.lastname: Malcolm
authors.forename: E
authors.initials: E
authors.lastname: Frei
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D002945:Cisplatin / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged
chemical_list: D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin